Tag: Sino Biopharmaceutical
Sino Biopharmaceutical Announces 2020 First Quarterly Results
Revenue was approximately RMB6.22 Billion;Profit Attributable to Owners of the Parent was approximately RMB862 Million
Sino Biopharmaceutical Limited ("Sino...
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso...
Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new drug application...
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for...
Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the...
Sino Biopharmaceutical Announces 2019 Third Quarterly Results
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in...
